STOCK TITAN

Guardant Health - GH STOCK NEWS

Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.

Overview of Guardant Health

Guardant Health is a precision oncology company that specializes in liquid biopsy tests and advanced genomic diagnostics. As a leader in the field of liquid biopsy and cancer diagnostics, the company has developed innovative, non-invasive tools that enable oncologists to access and sequence tumor DNA, thereby providing critical insights into cancer biology. Its robust suite of tests is designed for various clinical applications including treatment selection, detection of minimal residual disease, and broader gene panel analyses for immuno-oncology research.

Core Business Areas

Guardant Health operates at the intersection of advanced technology and medical science to revolutionize the way cancer is diagnosed and monitored. The company offers a comprehensive range of services, including:

  • Liquid Biopsy Testing: Non-invasive blood tests that analyze circulating tumor DNA to inform treatment decisions and monitor disease progression.
  • Companion Diagnostics: FDA-approved assays that help guide targeted cancer therapies ensuring that patients receive tailored treatment options.
  • Molecular Residual Disease (MRD) Testing: Tumor-agnostic tests designed to detect molecular evidence of cancer recurrence, enhancing post-treatment monitoring.
  • Research and Development Services: End-to-end support in regulatory consultancy and clinical trial referral, aiding clinical research and collaboration.

Market Position and Industry Impact

Guardant Health has established a significant presence in the precision oncology landscape by harnessing advanced data analytics and genomics. Its liquid biopsy solutions provide a safer, more efficient alternative to traditional tissue biopsies, thus facilitating faster and more accurate diagnostic processes. The company is also known for contributing to the broadening of cancer data acquisition, a crucial factor in driving discovery and innovation in cancer treatment and research. The integration of real-world data with artificial intelligence analytics has positioned Guardant Health as a valuable partner in both clinical and research settings, offering insights that have the potential to influence treatment protocols and clinical guidelines.

Operational Excellence and Scientific Rigor

At the core of Guardant Health's operations is a rigorous dedication to scientific accuracy and clinical validation. Every test is backed by detailed research and validated methodologies that ensure precise outcomes. The company emphasizes a strong ethical foundation by ensuring that its products are developed with a focus on patient safety and diagnostic integrity. This approach not only enhances trust among clinicians but also positions the firm as an authoritative voice in the field of oncology diagnostics.

Competitive Landscape and Differentiation

In a competitive market where several companies vie to innovate in cancer diagnostics, Guardant Health differentiates itself through its comprehensive approach to liquid biopsy technology. The company’s ability to offer a spectrum of tests across various stages of cancer care—ranging from early detection to monitoring minimal residual disease—illustrates its commitment to improving patient outcomes. Additionally, its successful legal defenses and insistence on data accuracy further underscore its focus on maintaining high standards across all areas of operation.

Commitment to Innovation and Data-Driven Discoveries

Guardant Health’s approach is deeply rooted in the belief that conquering cancer is as much a data problem as it is a medical challenge. Through the creation and application of advanced sequencing techniques and comprehensive data analytics, the company is continuously expanding its product offerings and clinical insights. This data-centric approach not only fuels ongoing innovation but also supports extensive research collaborations that are pivotal for furthering advancements in cancer care.

Conclusion

Overall, Guardant Health represents a forward-thinking enterprise in the realm of precision oncology, offering groundbreaking diagnostic solutions that bridge the gap between advanced technology and clinical practice. Its commitment to non-invasive testing, rigorous validation, and comprehensive clinical services helps demystify the complexities of cancer diagnostics, making it an essential component of modern medical research and patient care.

Rhea-AI Summary

Guardant Health (Nasdaq: GH) announced a private offering of $1 billion in convertible senior notes due 2027, with an additional $150 million option for initial purchasers. The notes will mature on November 15, 2027, and can be converted into cash or stock. Proceeds will fund capped call transactions and general corporate purposes, including R&D and potential acquisitions. This offering is subject to market conditions, and the notes are not registered under the Securities Act. Guardant Health is a leader in precision oncology, focusing on innovative blood tests for cancer detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.18%
Tags
none
-
Rhea-AI Summary

Guardant Health (GH) reported a 23% revenue increase to $74.6 million for Q3 2020, driven by a 16% rise in precision oncology revenue ($60.4 million). Development services surged 63% to $14.2 million. Clinical test volume rose 28% to 16,950, but biopharmaceutical tests fell 42% to 3,071. The company received FDA approval for Guardant360® CDx, the first liquid biopsy for comprehensive cancer profiling. Despite a gross profit rise to $53.4 million, operating expenses ballooned 113% to $127.6 million, leading to a net loss of $77.7 million ($0.78 per share). Guidance for 2020 remains unprovided due to COVID-19 uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
-
Rhea-AI Summary

Guardant Health, Inc. (Nasdaq: GH) will release its third-quarter 2020 financial results on November 5, 2020, after market closure. A conference call will follow at 1:30 p.m. PT. Investors can access the live audio webcast in the 'Investors' section of the company website. Guardant Health specializes in precision oncology, providing advanced blood tests like Guardant360 and GuardantOMNI to improve cancer patient outcomes and reduce healthcare costs. The company focuses on all cancer care stages, including early detection and selection of treatments for advanced cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
Rhea-AI Summary

Guardant Health, Inc. (Nasdaq: GH) has completed a public offering of 7.7 million shares of common stock, priced at $102.00 per share, including 700,000 shares from the underwriter's option. Notably, Guardant Health did not sell any shares nor receive proceeds from this offering, which was conducted by SoftBank Investment Advisers. The offering was made under an automatic shelf registration statement filed with the SEC, which became effective upon filing. J.P. Morgan Securities LLC served as the book-running manager for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
-
Rhea-AI Summary

Guardant Health has announced a public offering of 7,000,000 shares of its common stock priced at $102.00 per share, with the offering managed by J.P. Morgan Securities LLC. The shares are being sold by SoftBank Investment Advisers, and Guardant Health will not receive any proceeds from this sale. An additional option for underwriters to purchase up to 700,000 shares is also available. The offering is expected to close on October 9, 2020, pending customary closing conditions. This public offering is registered under Form S-3 with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
-
Rhea-AI Summary

Guardant Health (Nasdaq: GH) has initiated a public offering of 7,000,000 shares of its common stock, which will be sold exclusively by SoftBank Investment Advisers. An additional 700,000 shares may be available through an underwriter's option. Guardant Health is not participating in the sale and will not receive any proceeds. The offering is under an automatic shelf registration statement with the SEC and is subject to market conditions. J.P. Morgan Securities LLC is the sole book-running manager for the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
Rhea-AI Summary

Guardant Health (Nasdaq: GH) has released study findings from the SCRUM-Japan GOZILA trial, indicating that its Guardant360 liquid biopsy significantly enhances clinical trial enrollment for advanced gastrointestinal cancer. The study shows a 67% reduction in screening duration (median of 11 days vs. 33 days) and a 132% improvement in enrollment rates (9.5% vs. 4.1%) compared to traditional tissue genotyping. Furthermore, Guardant360 provides non-inferior treatment outcomes, detecting more actionable genomic alterations without compromising patient response rates or progression-free survival.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
-
Rhea-AI Summary

Guardant Health (Nasdaq: GH) will participate in the Morgan Stanley Virtual Healthcare Conference on September 15 at 8:45 a.m. Pacific Time. The event includes a fireside chat with company management, accessible via a live and archived webcast on their website. Guardant Health is a leader in precision oncology, utilizing proprietary blood tests and data analytics to enhance cancer treatment. Their offerings include the Guardant360® and GuardantOMNI® tests, primarily for advanced cancer patients, and the LUNAR program aimed at early-stage cancer detection and treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
conferences
-
Rhea-AI Summary

Guardant Health (Nasdaq: GH) will participate in two upcoming virtual investor conferences. The UBS Genomics 2.0 and Medtech Innovations Summit fireside chat is scheduled for August 11 at 9 a.m. PT / 12 p.m. ET. The Canaccord Virtual Growth Conference fireside chat will follow on August 13 at 1 p.m. PT / 4 p.m. ET. Interested parties can access the live and archived webcasts on the company's website. Guardant Health specializes in precision oncology and offers advanced blood tests that improve patient outcomes and reduce healthcare costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
conferences
Rhea-AI Summary

Guardant Health has received FDA approval for its Guardant360 CDx test, enabling tumor mutation profiling in patients with any solid malignant neoplasm. This test also serves as a companion diagnostic for non-small cell lung cancer patients with EGFR alterations, guiding treatment with Tagrisso. The approval is backed by data from over 5,000 samples, showing that patients identified via Guardant360 CDx have progression-free survival rates comparable to those from traditional methods. With over 150,000 tests performed and broad insurance coverage, this milestone enhances personalized cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
none

FAQ

What is the current stock price of Guardant Health (GH)?

The current stock price of Guardant Health (GH) is $40.58 as of April 4, 2025.

What is the market cap of Guardant Health (GH)?

The market cap of Guardant Health (GH) is approximately 5.0B.

What is Guardant Health's primary business focus?

Guardant Health specializes in developing and offering liquid biopsy tests for cancer diagnostics, utilizing advanced genomic testing and data analytics to support treatment selection and disease monitoring.

How do Guardant Health's liquid biopsy tests work?

The tests use a non-invasive method to analyze circulating tumor DNA from blood samples, providing oncologists with critical information that can guide treatment decisions and monitor disease progression.

What types of diagnostic assays does Guardant Health offer?

Guardant Health provides a range of assays including companion diagnostics for targeted therapies, molecular residual disease tests for post-treatment monitoring, and extensive gene panels for immuno-oncology research.

How does Guardant Health differentiate itself from competitors?

The company differentiates itself through a comprehensive portfolio of liquid biopsy tests, a strong commitment to scientific rigor, and successful legal defenses that validate its clinical and technological approaches.

What role does data analytics play in Guardant Health’s operations?

Data analytics is fundamental to its approach, enabling the company to harness vast amounts of cancer-related data to drive insights, support clinical decision-making, and fuel ongoing innovations in diagnostic testing.

Who are the primary users of Guardant Health's products?

Guardant Health's products are widely used by oncologists and clinical researchers, serving patients across all cancer stages through both diagnostic support and research collaboration.

What are the benefits of using a liquid biopsy?

Liquid biopsies offer a less invasive alternative to traditional tissue biopsies, reducing patient risk while providing rapid, accurate insights into tumor genetics and disease progression.

How does Guardant Health contribute to advancements in cancer research?

By integrating comprehensive cancer data acquisition with advanced genomic analysis, Guardant Health supports broad research collaborations that drive the discovery of new biomarkers and innovative therapeutic approaches.
Guardant Health

Nasdaq:GH

GH Rankings

GH Stock Data

5.01B
117.49M
4.71%
98.48%
6.4%
Diagnostics & Research
Services-medical Laboratories
Link
United States
PALO ALTO